Reprotech and the Next Era of Women’s Health: A FemTech Talk with Pranam Chatterjee

Reprotech and the Next Era of Women’s Health: A FemTech Talk with Pranam Chatterjee realiza-se a 17 de novembro de 2026, maze impact, em Lisboa.

Two days of hormone injections instead of fourteen. Eggs matured in a dish by engineered cells. A first baby born in Lima in December 2024. A Phase 3 trial under way in the US. That is the ambition behind Fertilo, the lead product of Gameto, a biotechnology company that just got aquired by Ferring Pharmaceuticals for $1.38 billion. On 17 November, we will have the pleasure of welcoming Pranam Chatterjee, one of the bright minds behind that ambition, for an informal evening conversation. The speaker Pranam Chatterjee is a cofounder and adviser of Gameto and Distinguished Assistant Professor of Bioengineering and Computer and Information Science at the University of Pennsylvania. An MIT PhD, he trained with George Church’s group at Harvard, where the cell engineering behind Gameto was developed. Today his lab uses generative AI to design proteins for infertility, rare neurodegenerative diseases and paediatric sarcomas. FemTech Talks - The evening Expect an open conversation about reproductive biotechnology, fertility and women’s health: the science, the path from lab to clinic, what investors and regulators need to see, and how innovation like this could reach Portugal. - Welcome from António Miguel,with a look at Maze’s investment in science based healthcare companies and FemTech Portugal - Inês Santos Silva on why funding women’s health research matters - Pranam Chatterjee on his work, followed by questions and open discussion Who should come Researchers, founders, investors, clinicians and anyone curious about where fertility and women’s health are heading. A small room, direct access to the speaker and the chance to meet people building in this space. Organised by FemTech Portugal x Maze, with support from TejoMed and AthenaDAO. FemTech Portugal is a non-profit association dedicated to accelerating women’s health innovation in Portugal. We bring together founders, healthcare professionals, researchers, investors, and advocates to connect, collaborate, and create a meaningful impact in women’s healthcare. Our mission is to build a strong and inclusive ecosystem that empowers innovation, supports collaboration, and amplifies the voices shaping the future of FemTech in Portugal and beyond. Maze is a Lisbon based impact investor, founded in 2013 by the Calouste Gulbenkian Foundation. Through venture capital funds, advisory services and acceleration programmes, it backs founders building science based healthcare and climate companies with social and environmental impact. TejoMed is a membership based primary care clinic in Lisbon. Its family medicine doctors see fewer patients, which leaves more time for personalised and preventive care. AthenaDAO is a community of researchers, funders and advocates working to advance women’s health research, education and funding. It sources, funds and incubates translational research, taking early science towards diagnostics, drugs and therapeutics.